Fragment-based research on potent, non-covalent inflammatory drugs goes forward
BioMAX beamline was used to discover selective, non-covalent inhibitors of Keap1– a common target against oxidative stress and inflammation. The result is a potent antithesis of the currently available drugs acting as covalent inhibitors.
Science news from MAX IV
Bacterial biomass conversion for renewable fuels
Imagine this future. Vehicles and machinery predominantly powered by renewable organic matter, a resource far better for the planet’s health than today’s predominate fossil fuels. What factors stand in the way for a global power transition to competitive, industrial-scale biomass conversion? A study in Nature Communications reveals one key piece of the puzzle using bacterial enzymes. At MAX IV’s BioMAX beamline, an international team of scientists has determined important rate-limiting steps of lignocellulose breakdown, a major hurdle in efficient biomass processing. The discovery holds promise for a significant reduction in manufacturing costs and faster adoption of new biomass-derived fuels to market.